125 related articles for article (PubMed ID: 10721089)
1. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.
Klarskov K; Johnson KL; Benson LM; Gleich GJ; Naylor S
Adv Exp Med Biol; 1999; 467():461-8. PubMed ID: 10721089
[TBL] [Abstract][Full Text] [Related]
2. Structural characterization of a case-implicated contaminant, "Peak X," in commercial preparations of 5-hydroxytryptophan.
Klarskov K; Johnson KL; Benson LM; Cragun JD; Gleich GJ; Wrona M; Jiang XR; Dryhurst G; Naylor S
J Rheumatol; 2003 Jan; 30(1):89-95. PubMed ID: 12508395
[TBL] [Abstract][Full Text] [Related]
3. On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome.
Williamson BL; Johnson KL; Tomlinson AJ; Gleich GJ; Naylor S
Toxicol Lett; 1998 Oct; 99(2):139-50. PubMed ID: 9817085
[TBL] [Abstract][Full Text] [Related]
4. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome.
Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S
Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716
[TBL] [Abstract][Full Text] [Related]
5. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan.
Michelson D; Page SW; Casey R; Trucksess MW; Love LA; Milstien S; Wilson C; Massaquoi SG; Crofford LJ; Hallett M
J Rheumatol; 1994 Dec; 21(12):2261-5. PubMed ID: 7699627
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
Naylor S; Williamson BL; Johnson KL; Gleich GJ
Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
[TBL] [Abstract][Full Text] [Related]
7. Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome.
Klarskov K; Gagnon H; Boudreault PL; Normandin C; Plancq B; Marsault E; Gleich GJ; Naylor S
Toxicol Lett; 2018 Jan; 282():71-80. PubMed ID: 29037509
[TBL] [Abstract][Full Text] [Related]
8. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
[TBL] [Abstract][Full Text] [Related]
10. Safety of 5-hydroxy-L-tryptophan.
Das YT; Bagchi M; Bagchi D; Preuss HG
Toxicol Lett; 2004 Apr; 150(1):111-22. PubMed ID: 15068828
[TBL] [Abstract][Full Text] [Related]
11. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome.
Williamson BL; Benson LM; Tomlinson AJ; Mayeno AN; Gleich GJ; Naylor S
Toxicol Lett; 1997 Jul; 92(2):139-48. PubMed ID: 9295237
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
[TBL] [Abstract][Full Text] [Related]
13. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
[No Abstract] [Full Text] [Related]
14. Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography.
Toyo'oka T; Yamazaki T; Tanimoto T; Sato K; Sato M; Toyoda M; Ishibashi M; Yoshihira K; Uchiyama M
Chem Pharm Bull (Tokyo); 1991 Mar; 39(3):820-2. PubMed ID: 2070471
[TBL] [Abstract][Full Text] [Related]
15. Contaminants in biotechnologically manufactured L-tryptophan.
Simat T; van Wickern B; Eulitz K; Steinhart EH
J Chromatogr B Biomed Appl; 1996 Oct; 685(1):41-51. PubMed ID: 8930752
[TBL] [Abstract][Full Text] [Related]
16. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
[TBL] [Abstract][Full Text] [Related]
17. Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome.
Hill RH; Caudill SP; Philen RM; Bailey SL; Flanders WD; Driskell WJ; Kamb ML; Needham LL; Sampson EJ
Arch Environ Contam Toxicol; 1993 Jul; 25(1):134-42. PubMed ID: 8346973
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and analysis of contaminants in ems-related tryptophan.
Steinhart H; van Wickern B; Meyer K; Simat T
Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
[No Abstract] [Full Text] [Related]
19. Analytical characterization of peptide contaminants of L-tryptophan.
Barnhart ER; Maggio VL; Alexander LR; Reilly MC; Gelbaum LT; Turner WE; Hine TK; Needham LL
Arch Environ Contam Toxicol; 1996 Jan; 30(1):142-8. PubMed ID: 8579384
[TBL] [Abstract][Full Text] [Related]
20. [A case of the eosinophilia-myalgia syndrome].
Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
